The Prevalence of Inflammatory Bowel Disease (IBD) in Patients with Multiple Sclerosis (MS): A Systematic Review and Meta‑Analysis

Amirreza Nasirzadeh, Reza Jahanshahi, Mahsa Ghajarzadeh, Aida Mohammadi, Abdorreza Naser Moghadasi


Background: This systematic review and meta‑analysis aim to update the pooled prevalence of Inflammatory bowel disease (IBD) in patients with multiple sclerosis (MS). Methods: Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched for references of the included studies, and conference abstracts that were published up to September 2021. Results: The literature search revealed 5719 articles, after deleting duplicates 3616 remained. Finally, 17 studies were included. The pooled prevalence of IBD in MS was 1% (I2 = 96.3%, P < 0.001). The pooled odds ratio of developing IBD in MS cases was 1.36 (95% CI: 1.1–1.6) (I2 = 58.3, P = 0.01). Conclusions: The results of this systematic review and meta‑analysis show that the pooled prevalence of IBD in MS patients was 1% and the pooled odds ratio of developing IBD in MS cases was 1.36.



Inflammatory bowel disease; multiple sclerosis; prevalence


Ghajarzadeh M, Mahsa O, Sauraian MA, Moghadasi AN,

Azimi A. Emotional intelligence (EI) of patients with multiple

sclerosis (MS). Iran J Public Health 2014;43:1550‑6.

Mirmosayyeb O, Shaygannejad V, Nehzat N, Mohammadi A,

Ghajarzadeh M. Prevalence of seizure/epilepsy in patients with

multiple sclerosis: A systematic review and meta‑analysis. Int J

Prev Med 2021;12:14.

Azimi A, Hanaei S, Sahraian MA, Mohammadifar M,

Ramagopalan SV, Ghajarzadeh M. Prevalence of sexual

dysfunction in women with multiple sclerosis: A systematic

review and meta‑analysis. Maedica 2019;14:408‑12.

Ghajarzadeh M, Jalilian R, Eskandari G, Sahraian MA, Azimi A,

Mohammadifar M. Fatigue in multiple sclerosis: Relationship

with disease duration, physical disability, disease pattern, age

and sex. Acta Neurologica Belgica 2013;113:411‑4.

Ghajarzadeh M, Mohammadi A, Sahraian MA. Risk of cancer in

multiple sclerosis (MS): A systematic review and meta‑analysis.

Autoimmun Rev 2020;19:102650. doi: 10.1016/j.autrev.


Jalilian R, Ghajarzadeh M, Fateh R, Togha M, Sahraian MA,

Azimi A. Comparison of sleep quality in women with migraine

moreover, multiple sclerosis. Acta Medica Iranica 2014;52:690‑3.

Azimi A, Doosti R, Samani SMV, Roostaei B, Gashti SH,

Navardi S, et al. Psychometric properties of the persian version

of the PARADISE‑24 questionnaire. Int J Prev Med 2021;12:50.

Braunstein JB, Anderson GF, Gerstenblith G, Weller W,

Niefeld M, Herbert R, et al. Noncardiac comorbidity increases

preventable hospitalizations and mortality among Medicare

beneficiaries with chronic heart failure. J Am Coll Cardiol


Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D,

Vollmer T. Comorbidity delays diagnosis and increases disability

at diagnosis in MS. Neurology 2009;72:117‑24.

Kelsen JR, Russo P, Sullivan KE. Early‑onset inflammatory

bowel disease. Immunol Allergy Clin 2019;39:63‑79.

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G,

et al. A systematic review of the incidence and prevalence

of autoimmune disease in multiple sclerosis. Mult Scler J


Alkhawajah MM, Caminero AB, Freeman HJ, Oger JJ. Multiple

sclerosis and inflammatory bowel diseases: What we know and

what we would need to know! Mult Scler J 2013;19:259‑65.

Kimura K, Hunter SF, Thollander MS, Loftus EV Jr, Melton III LJ,

O’Brien PC, et al. Concurrence of inflammatory bowel disease

and multiple sclerosis. Mayo Clinic Proc 2000;75:802‑6.

Yang Y, Musco H, Simpson‑Yap S, Zhu Z, Wang Y, Lin X, et al.

Investigating the shared genetic architecture between multiple

sclerosis and inflammatory bowel diseases. Nat Commun

;12:1‑12. doi: 10.1038/s41467‑021‑25768‑0.

Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role

of tumor necrosis factor and receptors in models of multiorgan

failure, rheumatoid arthritis, multiple sclerosis and inflammatory

bowel disease. Immunol Rev 1999;169:175‑94.

Kosmidou M, Katsanos AH, Katsanos KH, Kyritsis AP,

Tsivgoulis G, Christodoulou D, et al. Multiple sclerosis

and inflammatory bowel diseases: A systematic review and

meta‑analysis. J Neurol 2017;264:254‑9.

Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al.

Assessing risk of bias in prevalence studies: Modification of

an existing tool and evidence of interrater agreement. J Clin

Epidemiol 2012;65:934‑9.

Wang X, Wan J, Wang M, Zhang Y, Wu K, Yang F. Multiple

sclerosis and inflammatory bowel disease: A systematic review

and meta-analysis. Ann Clin Transl Neurol 2022;9:132‑40.

Kirby S, Brown M, Murray T, Andreou P, Fisk J, Stadnyk K,

et al., editors. Progression of multiple sclerosis in patients

with other autoimmune diseases. Multiple Sclerosis. London

NW1 3BH, England: Hodder Arnold, Hodder Headline Plc 338

Euston Road; 2005;11:S28-9.

Nielsen NM, Frisch M, Rostgaard K, Wohlfahrt J, Hjalgrim H,

Koch‑Henriksen N, et al. Autoimmune diseases in patients with

multiple sclerosis and their first‑degree relatives: A nationwide

cohort study in Denmark. Mult Scler J 2008;14:823‑9.

Castelo‑Branco A, Chiesa F, Bengtsson CE, Lee S, Minton NN,

Niemcryk S, et al. Non‑infectious comorbidity in patients

with multiple sclerosis: A national cohort study in Sweden.

Mult Scler J Exp Transl Clin 2020;6:2055217320947761. doi:


Gupta G, Gelfand JM, Lewis JD. Increased risk for

demyelinating diseases in patients with inflammatory bowel

disease. Gastroenterology 2005;129:819‑26.

Minuk G, Lewkonia R. Possible familial association of multiple

sclerosis and inflammatory bowel disease. N Engl J Med


De Felice KM, Novotna M, Enders FT, Faubion WA,

Tremaine WJ, Kantarci OH, et al. Idiopathic inflammatory

demyelinating disease of the central nervous system in patients

with inflammatory bowel disease: Retrospective analysis of

patients. Aliment Pharmacol Ther 2015;41:99‑107.

Katsanos AH, Katsanos KH. Inflammatory bowel disease and

demyelination: More than just a coincidence? Exp Rev Clin

Immunol 2014;10:363‑73.

Camara‑Lemarroy CR, Metz L, Meddings JB, Sharkey KA,

Wee Yong V. The intestinal barrier in multiple sclerosis:

Implications for pathophysiology and therapeutics. Brain


Shahmohammadi S, Sahraian MA, Shahmohammadi A,

Doosti R, Zare‑Mirzaie A, Naser Moghadasi A. A presentation

of ulcerative colitis after rituximab therapy in a patient with

multiple sclerosis and literature review. Mult Scler Relat Disord


Lin CH, Kadakia S, Frieri M. New insights into an autoimmune

mechanism, pharmacological treatment and relationship between

multiple sclerosis and inflammatory bowel disease. Autoimmun

Rev 2014;13:114‑6.